Neurological Disorder Drugs Market to Expand Notably, Foresees Fairfield Market Research

The US Surges Ahead with Higher Early Diagnosis Rates, and Rapid Drug Commercialization.

London, March 06, 2023 (GLOBE NEWSWIRE) — Neurological disorders have been among the leading causes of mortality worldwide. Although a majority of neurological conditions predominantly tends to affect geriatric population, the congenital abnormalities can be detected at the time of birth, which instantly leads to early diagnosis and progress in long-term treatment. Both the rising prevalence, and a notably increasing rate of early diagnosis will collectively uphold the growth of neurological disorder drugs market. Some of the most common and serious neurological conditions include epilepsy, cerebral palsy, dementia, Parkinson’s, Alzheimer’s, and Huntington’s disease. The rate of prevalence has been seeing a stark rise. Strokes are also recording a mounting number of instances each year. This severely necessitates efficacious drugs and therapeutics for neurological disorders,” opines the analyst at Fairfield Market Research. The company in its new upcoming study intends to provide an insightful growth analysis and forecast of the global neurological disorder drugs market. Moreover, newer scientific breakthroughs, and neurological discoveries will continue to complement the expansion of market, says the report. Industry’s growing emphasis on addressing the minutest of neurological or psychological symptoms and signs is also likely to heavily contribute toward the growth of neurological disorder drugs market.

Get Sample Copy/TOC of Neurological Disorder Drugs Market at

Insights into Segmentation Analysis

While neurological disorders span a wide range of conditions with the various symptoms, the study highlights employment of several drug categories that are considered during neurological disorder treatments. In addition to antiepileptics, antipsychotics, analgesics, and anticholinergics mark some of the most commonly prescribed segments of neurological disorder medications. Primary research findings however suggest that corticosteroids remain the most commonly employed drug category in neurological disorder drugs market given their effectiveness in terms of reducing inflammation and treating multiple sclerosis.

Insights into Regional Analysis

Regional analysis of the global neurological disorder drugs market reveals dominance of North America, which is likely to prevail through the end of forecast period. The primacy of the US in both drug R&D, and manufacturing spaces will continue to create a favorable growth environment for the region’s neurological disorder drugs market growth. Frequent drug approvals from the US FDA, in addition to shooting investments in the field of neurobiology, are expected to account for the incessant market growth here, leading the global landscape. The region has been at the forefront in terms of the prevalence of dementia, and Alzheimer’s, as well as faster drug commercialization. Higher consumer awareness regarding the symptoms of neurological disorder(s) that leads to early diagnosis and treatment later, also contributes toward the top positioning of North American market. Moreover, the associated reimbursement policies are supportive, which will remain a prominent growth elevator for the market here.

Leading Industry Players

The worldwide neurological disorder drugs market report would cover the detailed strategic profiles and competitive analysis of some of the most prominent company names. A few of the industry leaders covered in the report include Amgen Inc., Teva Pharmaceuticals, Pfizer Inc., Novartis, AstraZeneca, Neurocrine Biosciences Inc., Eli Lilly, UCB S.A., Ionis Pharmaceuticals, BioMarin Pharmaceutical Inc., and Biogen.

Do You Have Any Query or Specific Requirement? Request for Custom Research:

The Global Neurological Disorder Drugs Market Is Segmented As Below:

By Drug Type

  • Antipsychotic
  • Antiepileptic
  • Anticholinergic
  • Analgesics
  • Hypnotic & Sedative
  • Anticoagulants
  • Antihypertensive

By Disease Type

  • Epilepsy
  • Parkinson’s disease
  • Alzheimer’s disease
  • Cerebrovascular disease
  • Multiple Sclerosis
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific

Key Elements Included In The Study: Global Neurological Disorder Drugs Market

  • Neurological Disorder Drugs Market by Product/Technology/Grade, Application/End-user, and Region
  • Executive Summary (Opportunity Analysis and Key Trends)
  • Historical Market Size and Estimates, Value, 2018 – 2021
  • Market Value at Regional and Country Level, 2022 – 2029
  • Market Dynamics and Economic Overview
  • Market Size in Value, Growth Rates, and Forecast Figures, 2022 – 2029
  • Competitive Intelligence with Financials, Key Developments, and Portfolio of Leading Companies 
  • Regional and Product/Grade/Application/End-user Price Trends Analysis
  • Value Chain and Five Force’s Analysis
  • Regional/Sub-region/Country Market Size and Trend Analysis
  • Company Market Share Analysis and Key Player Profiles

Learn More About the Report Inclusions, and Research Methodology:

About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.


Fairfield Market Research
London, UK
UK +44 (0)20 30025888   
USA (Toll-free) +1 (844) 3829746 
Email: [email protected]

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.